With reference to Tumour-Agnostic therapies and Antibody-Drug Conjugates (ADCs), consider the following statements: 1. Tumour-agnostic therapies treat cancer based on the organ of origin rather than the tumor's molecular characteristics. 2. Trastuzumab Deruxtecan utilizes monoclonal antibodies to deliver cytotoxic drugs directly to HER2-positive cancer cells. Which of the statements given above is/are correct?

Question

Accepted Answer

B. 2 only — Statement 1 is incorrect because tumour-agnostic therapies treat cancer based on specific genetic or molecular markers (like HER2), regardless of the organ of origin. Statement 2 is correct as Trastuzumab Deruxtecan is an ADC that uses a monoclonal antibody to bind to HER2 receptors and deliver a cytotoxic drug directly into the cancer cell.

CDSCO Approves India's First Tumour-Agnostic ADC Therapy

NITI Aayog Report on Tax Decriminalisation